

PCR-/NAT *Chlamydia pneumoniae* (RV 540) Mai 2026



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

Proben Nr.	Erwartet / expected		Probenzusammensetzung / Sample composition
540 260519 01	+	61	<i>Chlamydia pneumoniae</i> (~ 5x10 ³ IFU/mL)
540 260519 02	++	61	<i>Chlamydia pneumoniae</i> (~ 5x10 ⁴ IFU/mL)
540 260519 03	Ø	62	<i>Bordetella pertussis</i> (~ 1x10 ⁴ CFU/mL)
540 260519 04	Ø	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n</i> = 151		Proben Nr. (Sample no.)				Inhibition				
Befund Result		01	02	03	04		01	02	03	04
Positiv	150	150	1	0		n.d.	3	3	3	3
Negativ	1	1	150	151		nein no	148	148	148	148
Fraglich Questionable	0	0	0	0		ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number)	NAT richtig positiv True positive results				NAT richtig negativ True negative results			
	01		02		03		04	
	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%
AID CAP Bac PCR Kit (n= 3)	3	100	3	100	3	100	3	100
ARGENE Chla/Myco pneumo R-GENE (n= 3)	3	100	3	100	3	100	3	100
Amplex eazypex PneumoBug expert (n= 3)	3	100	3	100	3	100	3	100
AmpliGnost C. pneumoniae (n= 2)	2	100	2	100	2	100	2	100
BioGX for BD MAX M.pn, L.pn, C.pn, Pneumocystis jirovecii (n= 2)	2	100	2	100	1	50	2	100
BioGX for BD MAX M.pn, L.pn, C.pn (n= 4)	4	100	4	100	4	100	4	100
BioFire FILMARRAY Resp. Panel 2.1 plus (n= 3)	3	100	3	100	3	100	3	100
Biolegio ReadyMax b-CAP Assay (n= 3)	3	100	3	100	3	100	3	100

CerTest VIASURE C.pn, M.pn, L.pn (n= 5)	4	80	4	80	5	100	5	100
GeneProof C. pneumoniae (n= 10)	10	100	10	100	10	100	10	100
Luminex NxTAG Respiratory Pathogen (n= 4)	4	100	4	100	4	100	4	100
ampliCube Resp. panel 1.1 / 1.1LC (n = 12)	12	100	12	100	12	100	12	100
QIAstat-Dx Resp. Sars CoV-2 panel (n= 2)	2	100	2	100	2	100	2	100
Roche UC-TIB-Respi-BAC-2 (n= 9)	9	100	9	100	9	100	9	100
Seegene Allplex Pneumobacter (n= 20)	20	100	20	100	20	100	20	100
Seegene Allplex Resp. Panel 4 (n= 22)	22	100	22	100	22	100	22	100
TIB Molbiol LightMix C. pneumoniae (n= 5)	5	100	5	100	5	100	5	100
RIDAGENE or RIDAUNITY CAP Bac (n= 6)	6	100	6	100	6	100	6	100
In house PCR assay (n= 18)	18	100	18	100	18	100	18	100
Other commercial tests (n= 15)	15	100	15	100	15	100	15	100

Comments:

1. The following tests are listed under "Other commercial tests": Altona FlexStar MP & CP PCR Detection Mix (1x), Anatolia Geneworks Bosphore C. pneumoniae Detection Kit (1x), Anatolia Geneworks Bosphore Atypical CAP Panel Kit (1x), BioGX for BD MAX M. pneumoniae, Legionella spp., C. pneumoniae, C. psittaci (1x), DNA-TECHNOLOGY C. pneumoniae, M. pneumoniae multiplex (1x), ELITechGroup Respiratory Bacterial ELITe MGB Panel (4x), Genetic signatures Respiratory Atypical Bacteria Detection Panel (RP020) (1x), PathoFinder RespiFinder 2Smart (1x), Roche UC-TIB-Respi-BAC-1 (1x) and Roche UC-TIB-Respi-BAC-4 (1x).